Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
Ovarian cancer is the fifth leading cause of deaths from cancer in women
Read More
Tag: Corcept Therapeutics
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
- Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
- ErVimmune raises 17m euros in funding to develop cancer vaccine
- Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
